Application
Fig1: Western blot analysis of Phospho-p53(S392) on different lysates using anti-Phospho-p53(S392) antibody at 1/1,000 dilution. Positive control: Lane 1: 293 Lane 2: F9Application
Fig2: Immunohistochemical analysis of paraffin-embedded human gastric carcinoma tissue using anti-Phospho-p53(S392) antibody. Counter stained with hematoxylin.Application
Fig3: Immunohistochemical analysis of paraffin-embedded mouse prostate tissue using anti-Phospho-p53(S392) antibody. Counter stained with hematoxylin.| Product Name | Phospho-p53(S392) [SI17-04] |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | Antigen NY-CO-13 antibody BCC7 antibody Cellular tumor antigen p53 antibody FLJ92943 antibody LFS1 antibody Mutant tumor protein 53 antibody p53 antibody p53 tumor suppressor antibody P53_HUMAN antibody Phosphoprotein p53 antibody Tp53 antibody Transformation related protein 53 antibody TRP53 antibody Tumor protein 53 antibody Tumor protein p53 antibody Tumor suppressor p53 antibody |
| Product description | p53 is a DNA-binding, oligomerization domain- and transcription activation domain-containing tumor suppressor that upregulates growth arrest and apoptosis-related genes in response to stress signals, thereby influencing programmed cell death, cell differentiation and cell cycle control mechanisms. p53 localizes to the nucleus yet can be chaperoned to the cytoplasm by the negative regulator MDM2, an E3 ubiquitin ligase that is upregulated in the presence of active p53, where MDM2 polyubiquitinates p53 for proteasome targeting. p53 can assemble into tetramers in the absence of DNA, fluctuates between latent and active (DNA-binding) conformations, and is differentially activated through posttranslational modifications including phosphorylation and acetylation. Mutations in the DNA-binding domain (DBD) (amino acids 110-286) of p53 can compromise energetically favorable association with cis elements and are implicated in several human cancers. Phosphorylation of p53 at residue Thr 155 is mediated by the COP9 signalosome (CSN) and targets p53 to ubiquitin-26S Proteasome-dependent degradation. |
| Immunogen | Synthetic phospho-peptide corresponding to residues surrounding Ser392 of human p53. |
| Modification | p-S392 |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG |
| Host Species | Recombinant rabbit |
| Tested Applications | WBIHCIP |
| WB:1:1,000-1:5,000 IHC:1:50-1:200 |
|
| Species Reactivity | HumanMouseRat |
| Concentration | 1mg/ml |
| Alternative Names | Antigen NY-CO-13 antibody BCC7 antibody Cellular tumor antigen p53 antibody FLJ92943 antibody LFS1 antibody Mutant tumor protein 53 antibody p53 antibody p53 tumor suppressor antibody P53_HUMAN antibody Phosphoprotein p53 antibody Tp53 antibody Transformation related protein 53 antibody TRP53 antibody Tumor protein 53 antibody Tumor protein p53 antibody Tumor suppressor p53 antibody |
|---|---|
| Molecular Weight(MW) | 53 kDa |
| Cellular Localization | Cytoplasm, Nucleus, Endoplasmic reticulum, Mitochondrion matrix. |
Application
Fig1: Western blot analysis of Phospho-p53(S392) on different lysates using anti-Phospho-p53(S392) antibody at 1/1,000 dilution. Positive control: Lane 1: 293 Lane 2: F9
Application
Fig2: Immunohistochemical analysis of paraffin-embedded human gastric carcinoma tissue using anti-Phospho-p53(S392) antibody. Counter stained with hematoxylin.
Application
Fig3: Immunohistochemical analysis of paraffin-embedded mouse prostate tissue using anti-Phospho-p53(S392) antibody. Counter stained with hematoxylin.| Positive Control | F9, human gastric carcinoma tissue, mouse prostate tissue. |
|---|---|
| Application Notes | WB:1:1,000-1:5,000 IHC:1:50-1:200 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
